The Efficacy and Safety of Decitabine in Combination with ATRA, G-CSF and Low Dose Cytarabine(Dlaag Regimen)in Relapsed/Refractory Acute Myeloid Leukemia Not Suitable for Strong Chemotherapy : A Phase 2, Prospective, Single-Arm, Multicenter Study

被引：0
|
作者：
Yang, Li [1 ]
Liu, Ligen [2 ]
Zhao, Limin [1 ]
Lu, Yingting [1 ]
Zhang, Jing [1 ]
Sun, Lihua [3 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Tongren Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Tongren Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China
[3] Fudan Univ, Qingpu Branch, Dept Hematol, Zhongshan Hosp, Shanghai, Peoples R China
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131671
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5108
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
    David Martínez-Cuadrón
    Blanca Boluda
    Pilar Martínez
    Juan Bergua
    Rebeca Rodríguez-Veiga
    Jordi Esteve
    Susana Vives
    Josefina Serrano
    Belen Vidriales
    Olga Salamero
    Lourdes Cordón
    Amparo Sempere
    Ana Jiménez-Ubieto
    Julio Prieto-Delgado
    Marina Díaz-Beyá
    Ana Garrido
    Celina Benavente
    José Antonio Pérez-Simón
    Federico Moscardó
    Miguel A. Sanz
    Pau Montesinos
    Annals of Hematology, 2018, 97 : 763 - 772
  • [22] A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
    Uy, G. L.
    Rettig, M. P.
    Stone, R. M.
    Konopleva, M. Y.
    Andreeff, M.
    McFarland, K.
    Shannon, W.
    Fletcher, T. R.
    Reineck, T.
    Eades, W.
    Stockerl-Goldstein, K.
    Abboud, C. N.
    Jacoby, M. A.
    Westervelt, P.
    DiPersio, J. F.
    BLOOD CANCER JOURNAL, 2017, 7 : e542 - e542
  • [23] A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
    G L Uy
    M P Rettig
    R M Stone
    M Y Konopleva
    M Andreeff
    K McFarland
    W Shannon
    T R Fletcher
    T Reineck
    W Eades
    K Stockerl-Goldstein
    C N Abboud
    M A Jacoby
    P Westervelt
    J F DiPersio
    Blood Cancer Journal, 2017, 7 : e542 - e542
  • [24] Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial
    Fu, Wei-Jun
    Wang, Ya-Fei
    Zhao, Hong-Guo
    Niu, Ting
    Fang, Bai-Jun
    Liao, Ai-Jun
    Bai, Hai
    Lu, Jin
    BMC CANCER, 2022, 22 (01)
  • [25] Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial
    Wei-Jun Fu
    Ya-Fei Wang
    Hong-Guo Zhao
    Ting Niu
    Bai-Jun Fang
    Ai-Jun Liao
    Hai Bai
    Jin Lu
    BMC Cancer, 22
  • [26] A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
    Martinez-Cuadron, David
    Boluda, Blanca
    Martinez, Pilar
    Bergua, Juan
    Rodriguez-Veiga, Rebeca
    Esteve, Jordi
    Vives, Susana
    Serrano, Josefina
    Vidriales, Belen
    Salamero, Olga
    Cordon, Lourdes
    Sempere, Amparo
    Jimenez-Ubieto, Ana
    Prieto-Delgado, Julio
    Diaz-Beya, Marina
    Garrido, Ana
    Benavente, Celina
    Antonio Perez-Simon, Jose
    Moscardo, Federico
    Sanz, Miguel A.
    Montesinos, Pau
    ANNALS OF HEMATOLOGY, 2018, 97 (05) : 763 - 772
  • [27] Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
    David Martínez-Cuadrón
    Blanca Boluda
    Pilar Martínez
    Juan Bergua
    Rebeca Rodríguez-Veiga
    Jordi Esteve
    Susana Vives
    Josefina Serrano
    Belen Vidriales
    Olga Salamero
    Lourdes Cordón
    Amparo Sempere
    Ana Jiménez-Ubieto
    Julio Prieto-Delgado
    Marina Díaz-Beyá
    Ana Garrido
    Celina Benavente
    José Antonio Pérez-Simón
    Federico Moscardó
    Miguel A. Sanz
    Pau Montesinos
    Annals of Hematology, 2018, 97 : 923 - 923
  • [28] Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
    Li, Yan-Yan
    Ge, Shuai-Shuai
    Huang, Yuan-Hong
    Xu, Ming-Zhu
    Wan, Chao-Ling
    Tan, Kai-Wen
    Tao, Tao
    Zhou, Hai-Xia
    Xue, Sheng-Li
    Dai, Hai-Ping
    BLOOD CANCER JOURNAL, 2024, 14 (01)
  • [29] Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
    Yan-Yan Li
    Shuai-Shuai Ge
    Yuan-Hong Huang
    Ming-Zhu Xu
    Chao-Ling Wan
    Kai-Wen Tan
    Tao Tao
    Hai-Xia Zhou
    Sheng-Li Xue
    Hai-Ping Dai
    Blood Cancer Journal, 14
  • [30] Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia
    Lei, Meiqing
    Liu, Limin
    Wang, Zhiming
    Wu, Depei
    INDIAN JOURNAL OF CANCER, 2019, 56 (02) : 167 - 172
12345